You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Barriers and opportunities for gemcitabine in pancreatic cancer therapy
Contributor:
Beutel, Alica K.;
Halbrook, Christopher J.
Published:
American Physiological Society, 2023
Published in:
American Journal of Physiology-Cell Physiology, 324 (2023) 2, Seite C540-C552
Language:
English
DOI:
10.1152/ajpcell.00331.2022
ISSN:
0363-6143;
1522-1563
Origination:
Footnote:
Description:
Pancreatic ductal adenocarcinoma (PDA) has become one of the leading causes of cancer-related deaths across the world. A lack of durable responses to standard-of-care chemotherapies renders its treatment particularly challenging and largely contributes to the devastating outcome. Gemcitabine, a pyrimidine antimetabolite, is a cornerstone in PDA treatment. Given the importance of gemcitabine in PDA therapy, extensive efforts are focusing on exploring mechanisms by which cancer cells evade gemcitabine cytotoxicity, but strategies to overcome them have not been translated into patient care. Here, we will introduce the standard treatment paradigm for patients with PDA, highlight mechanisms of gemcitabine action, elucidate gemcitabine resistance mechanisms, and discuss promising strategies to circumvent them.